GLAND PHARMA
Quarterly Results Analysis [Dec2024]
GLAND PHARMA Quarterly Results
Consolidated | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,384 Cr | ₹1,406 Cr | ₹1,402 Cr | ₹1,537 Cr | ₹1,545 Cr | ₹1,373 Cr | ₹1,209 Cr | ₹785 Cr |
Expenses | ₹1,024 Cr | ₹1,109 Cr | ₹1,137 Cr | ₹1,179 Cr | ₹1,189 Cr | ₹1,049 Cr | ₹915 Cr | ₹617 Cr |
Operating Income | ₹360 Cr | ₹297 Cr | ₹264 Cr | ₹359 Cr | ₹356 Cr | ₹324 Cr | ₹294 Cr | ₹168 Cr |
Other Income | ₹58 Cr | ₹60 Cr | ₹51 Cr | ₹42 Cr | ₹37 Cr | ₹53 Cr | ₹38 Cr | ₹39 Cr |
Interest | ₹23 Cr | ₹6 Cr | ₹6 Cr | ₹10 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹2 Cr |
Depreciation | ₹96 Cr | ₹94 Cr | ₹92 Cr | ₹93 Cr | ₹105 Cr | ₹81 Cr | ₹65 Cr | ₹38 Cr |
Profit Before Tax | ₹299 Cr | ₹257 Cr | ₹218 Cr | ₹298 Cr | ₹283 Cr | ₹290 Cr | ₹261 Cr | ₹111 Cr |
Profit After Tax | ₹205 Cr | ₹164 Cr | ₹144 Cr | ₹192 Cr | ₹192 Cr | ₹194 Cr | ₹194 Cr | ₹79 Cr |
EPS | ₹12.42 | ₹9.93 | ₹8.73 | ₹11.68 | ₹11.65 | ₹11.78 | ₹11.79 | ₹4.78 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLAND PHARMA | 0.6% | -9.5% | -16.7% |
SUN PHARMACEUTICAL INDUSTRIES | -3.4% | -0.2% | 18.1% |
DIVIS LABORATORIES | -2.3% | 3.4% | 55.5% |
CIPLA | -2.6% | -0.6% | 5.9% |
TORRENT PHARMACEUTICALS | -2.3% | -2.1% | 20.4% |
DR REDDYS LABORATORIES | -2.9% | -0.2% | -8.7% |
MANKIND PHARMA | 2.2% | 0.3% | 5% |
ZYDUS LIFESCIENCES | -1.5% | -3.2% | -11.1% |
LUPIN | -2.1% | -3.9% | 25.1% |
GLAND PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -1.55 % |
Y-o-Y | -10.43 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹1,384 Cr | -1.55 | |
Sep2024 | ₹1,406 Cr | 0.29 | |
Jun2024 | ₹1,402 Cr | -8.83 | |
Mar2024 | ₹1,537 Cr | -0.50 | |
Dec2023 | ₹1,545 Cr | 12.50 | |
Sep2023 | ₹1,373 Cr | 13.63 | |
Jun2023 | ₹1,209 Cr | 53.97 | |
Mar2023 | ₹785 Cr | - |
GLAND PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 21.17 % |
Y-o-Y | 1.00 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹360 Cr | 21.17 | |
Sep2024 | ₹297 Cr | 12.35 | |
Jun2024 | ₹264 Cr | -26.28 | |
Mar2024 | ₹359 Cr | 0.63 | |
Dec2023 | ₹356 Cr | 9.97 | |
Sep2023 | ₹324 Cr | 10.25 | |
Jun2023 | ₹294 Cr | 74.54 | |
Mar2023 | ₹168 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 23.10 % |
Y-o-Y | 12.79 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 26.01% | 23.10 | |
Sep2024 | 21.13% | 12.04 | |
Jun2024 | 18.86% | -19.16 | |
Mar2024 | 23.33% | 1.17 | |
Dec2023 | 23.06% | -2.29 | |
Sep2023 | 23.6% | -2.96 | |
Jun2023 | 24.32% | 13.38 | |
Mar2023 | 21.45% | - |
GLAND PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 25.17 % |
Y-o-Y | 6.69 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹205 Cr | 25.17 | |
Sep2024 | ₹164 Cr | 13.75 | |
Jun2024 | ₹144 Cr | -25.29 | |
Mar2024 | ₹192 Cr | 0.29 | |
Dec2023 | ₹192 Cr | -1.15 | |
Sep2023 | ₹194 Cr | -0.01 | |
Jun2023 | ₹194 Cr | 146.69 | |
Mar2023 | ₹79 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 27.17 % |
Y-o-Y | 19.08 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 14.79 % | 27.17 | |
Sep2024 | 11.63 % | 13.35 | |
Jun2024 | 10.26 % | -18.05 | |
Mar2024 | 12.52 % | 0.81 | |
Dec2023 | 12.42 % | -12.10 | |
Sep2023 | 14.13 % | -12.02 | |
Jun2023 | 16.06 % | 60.28 | |
Mar2023 | 10.02 % | - |
GLAND PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 25.08 % |
Y-o-Y | 6.61 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹12.42 | 25.08 | |
Sep2024 | ₹9.93 | 13.75 | |
Jun2024 | ₹8.73 | -25.26 | |
Mar2024 | ₹11.68 | 0.26 | |
Dec2023 | ₹11.65 | -1.10 | |
Sep2023 | ₹11.78 | -0.08 | |
Jun2023 | ₹11.79 | 146.65 | |
Mar2023 | ₹4.78 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD